Please ensure Javascript is enabled for purposes of website accessibility

Novavax Gets a Big Win for Its Flu Vaccine in Phase 3 Trial

By Taylor Carmichael - Mar 24, 2020 at 10:27AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After the biotech company needed a 1-for-20 reverse stock split last year to avoid being delisted, Novavax has hit a home run with NanoFlu.

On Tuesday, vaccine-specialist Novavax (NVAX 4.16%) reported positive news from the phase 3 trial for its flu vaccine, NanoFlu: The treatment met both the primary and secondary endpoints of the study. The stock was up 36% in early trading.

"These strong Phase 3 results align with and validate our previous clinical trials, in which NanoFlu showed higher HAI antibody responses than the leading flu vaccine for older adults," said CEO Stanley Erck. "We expect that both Fast Track designation and the accelerated approval pathway from the FDA will help Novavax bring NanoFlu to market as quickly as possible to address the serious public health threat of influenza." 

"Flu Shot" on Calendar

Image Source: Getty Images

The phase 3 trial evaluated the immunogenicity and safety of NanoFlu compared to Fluzone Quadrivalent, the vaccine sold by market-leader Sanofi (SNY -1.53%). NanoFlu demonstrated significantly higher geometric mean titers (GMT) and seroconversion rates (SCR) across all four flu strains included in the vaccine. In the trial, NanoFlu had 24% to 66% higher GMT responses than Fluzone Quadrivalent, and scored 11.4 to 20.4 percentage points higher for SCR.   

NanoFlu was also tested in four different flu strains not included in the vaccine, but circulating this year. Again the drug demonstrated significantly higher GMT and SCR scores than Fluzone Quadrivalent in all four strains. 

In an interview with the Washington Business Journal, Dr. Gregory Glenn, president of research and development for Novavax, said, "This is such a critical milestone to have positive pivotal trial data like this. It's transformational. Biotech companies, at the end of the day, only survive if they deliver success, if they deliver a clear pathway to licensure. It's a strange business, but our coinage really is clinical data -- and this is gold."  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$53.82 (4.16%) $2.15
Sanofi Stock Quote
Sanofi
SNY
$52.60 (-1.53%) $0.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.